MURAL ONCOLOGY PLC (MURA) Stock Price, Quote, News and Overview
NASDAQ:MURA - Nasdaq - IE000LK2BOB4 - Common Stock - Currency: USD
MURA Quote, Performance and Key Statistics
NASDAQ:MURA (6/13/2025, 8:24:43 PM)
2.46
-0.07 (-2.77%)
The current stock price of MURA is 2.46 USD. In the past month the price decreased by -2.77%. In the past year, price decreased by -23.84%.
MURA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.61 | 337.52B | ||
| AMGN | AMGEN INC | 14.22 | 158.74B | ||
| GILD | GILEAD SCIENCES INC | 14.21 | 136.81B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 116.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.94 | 57.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.16B | ||
| ARGX | ARGENX SE - ADR | 100.5 | 35.29B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.89 | 29.17B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.62B | ||
| NTRA | NATERA INC | N/A | 22.58B | ||
| BIIB | BIOGEN INC | 8.26 | 19.14B | ||
| INSM | INSMED INC | N/A | 17.98B |
Related stock screener links
About MURA
Company Profile
Mural Oncology Plc is a clinical-stage oncology company, which engages in the business of discovering and developing immunotherapies for patients with cancer. The firm is leveraging its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. The company leverages its in-cytokine biology, immune cell modulation and protein engineering capabilities to develop immunotherapies. The firm is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. Its portfolio of programs includes Nemvaleukin alfa (Nemvaleukin)-IL-2, IL-12, and IL-18. Nemvaleukin is an engineered interleukin-2 (IL-2) variant designed to harness the potent anti-cancer capabilities of high-dose rhIL-2 while minimizing toxicity by selectively activating cancer-fighting CD8 T cells and NK cells. The tumor-targeted split IL-12 program focuses on delivering the therapeutic potential of IL-12 by splitting it into inactive component.
Company Info
MURAL ONCOLOGY PLC
10 Earlsfort Terrace
DUBLIN IE
Employees: 116
Phone: 35319058020
MURAL ONCOLOGY PLC / MURA FAQ
What is the stock price of MURAL ONCOLOGY PLC today?
The current stock price of MURA is 2.46 USD. The price decreased by -2.77% in the last trading session.
What is the ticker symbol for MURAL ONCOLOGY PLC stock?
The exchange symbol of MURAL ONCOLOGY PLC is MURA and it is listed on the Nasdaq exchange.
On which exchange is MURA stock listed?
MURA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MURAL ONCOLOGY PLC stock?
9 analysts have analysed MURA and the average price target is 6.12 USD. This implies a price increase of 148.78% is expected in the next year compared to the current price of 2.46. Check the MURAL ONCOLOGY PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MURAL ONCOLOGY PLC worth?
MURAL ONCOLOGY PLC (MURA) has a market capitalization of 42.48M USD. This makes MURA a Nano Cap stock.
How many employees does MURAL ONCOLOGY PLC have?
MURAL ONCOLOGY PLC (MURA) currently has 116 employees.
What are the support and resistance levels for MURAL ONCOLOGY PLC (MURA) stock?
MURAL ONCOLOGY PLC (MURA) has a support level at 2.45 and a resistance level at 2.5. Check the full technical report for a detailed analysis of MURA support and resistance levels.
Should I buy MURAL ONCOLOGY PLC (MURA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MURA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MURA, evaluating the profitability, health, valuation and growth aspects
- MURAL ONCOLOGY PLC (MURA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MURAL ONCOLOGY PLC (MURA) Sales and EPS estimates to see what analysts future expectations are.
- MURAL ONCOLOGY PLC (MURA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MURAL ONCOLOGY PLC (MURA) Insider and Institutional Ownership to learn about the owners and their transactions.
- MURAL ONCOLOGY PLC (MURA) Stock Chart to make your own analysis
- MURAL ONCOLOGY PLC (MURA) Latest news and press-releases to stay up to date.
Does MURAL ONCOLOGY PLC (MURA) stock pay dividends?
MURA does not pay a dividend.
What is the Price/Earnings (PE) ratio of MURAL ONCOLOGY PLC (MURA)?
MURAL ONCOLOGY PLC (MURA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.81).
What is the Short Interest ratio of MURAL ONCOLOGY PLC (MURA) stock?
The outstanding short interest for MURAL ONCOLOGY PLC (MURA) is 4.39% of its float. Check the ownership tab for more information on the MURA short interest.
MURA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MURA. When comparing the yearly performance of all stocks, MURA is a bad performer in the overall market: 90.66% of all stocks are doing better.
MURA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MURA. MURA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MURA Financial Highlights
Over the last trailing twelve months MURA reported a non-GAAP Earnings per Share(EPS) of -7.81. The EPS increased by 46.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -98.98% | ||
| ROE | -121.18% | ||
| Debt/Equity | 0 |
MURA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to MURA. The Buy consensus is the average rating of analysts ratings from 9 analysts.